The 67th Annual Meeting of the American Society for Radiation Oncology (ASTRO) is taking place from September 27 to October 1, 2025, at the Moscone Center in San Francisco, with options to join via livestream or OnDemand. The exhibit hall will be open from September 28 to 30, showcasing the latest innovations in radiation medicine.
This year’s theme, “Rediscovering Radiation Medicine and Exploring New Indications,” highlights both the rich legacy of the field and its exciting future directions.
The meeting brings together radiation oncologists, researchers, and industry experts from around the world to exchange knowledge, present groundbreaking research, and explore new clinical applications of radiation therapy.
Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared highlights from Day 1 of ASTRO 2025:
A poster to look out for at ASTRO25.
“Here’s a poster to look out for at ASTRO25.
I’m bullish on this being the future of lung SBRT for linacs with 6-second HyperSight CBCT imaging capabilities.”
Better lung function preservation after SBRT.
“Yue Wang, a graduate student from Tianjin, is scheduled to present prospective data on PFT changes after SBRT and Surgery at ASTRO25.
Their preliminary data demonstrate what we generally see in practice, which is better lung function preservation after SBRT.”
The outcomes following HDR brachyablation for lung tumors.
“Investigators at UCLA previously reported the outcomes following HDR brachyablation for lung tumors treated from 2015 to 2019 (n = 25). In a contemporary update led by Michelle Eala, we now report our experience with this technique in patients treated from 2019 to 2022 (n=33) at ASTRO25. Local control = 98%!!
The combined experience will be published soon.”
QD as a safer and more effective treatment option for central lung tumors.
“A new study from UPMC (n=150) supports QD as a safer and more effective treatment option for central lung tumors treated with SBRT compared to QoD.”
The deleterious effects of using V5 lung constraints for thoracic radiation therapy.
“An important study presented at ASTRO25 demonstrates the deleterious effects of using V5 lung constraints for thoracic radiation therapy treatment planning and hopefully puts an end to this sad era in our field when some of us thought it mattered.”
Single-fraction lung SBRT
“A report co-authored by single-fraction lung SBRT enthusiasts demonstrates how (not) often this treatment schedule is being used in the US. The manuscript is currently undergoing minor revisions and will be published soon.”
Having Less financial distress after treatment.
“An inspiring report out of Wichita, Kansas, shows patients undergoing radiation therapy have LESS financial distress after treatment.”
Observations across 5 urban centers in Arizona.
“A RWE study presented at ASTRO25, reporting their observations across 5 urban centers in Arizona, demonstrates the importance of systematic invasive mediastinal staging before lung SBRT for stage I NSCLC.”
Read Further.
From WCLC25 in Barcelona to ASTRO25 in San Francisco.
“From WCLC25 in Barcelona to ASTRO25 in San Francisco, our team is presenting these data once again on in-field progression, with an outstanding narration by Shannon Nesbitt, who is pursuing a career in thoracic surgery.”
Single-fraction lung SBRT results from British Columbia.
“Single-fraction lung SBRT results from British Columbia further support this as a great treatment option for stage I NSCLC.”
An intriguing poster at ASTRO25
“An intriguing poster at ASTRO25 demonstrates that major North American TV Shows are leading viewers to believe radiation might cause “internal melting, burning, or crumbling, or even a food allergy”.”
When surgery is the better local therapy option for NSCLC.
“Updated data from the Max Diehn lab to be presented at ASTRO25 moves us closer to a day when an NGS test (pathogenic KEAP1/NRF2) can predict when surgery is the better local therapy option for NSCLC.”
Anti-cancer therapy that could certainty confound the results.
“The results of this study, led by Kara Marieruicci, are mind-boggling. While most clinical trials of systemic therapy for NSCLC, including many randomized phase II and III studies, allow for on-trial RT (off protocol), NONE (0%) of them actually collect any data on this additional anti-cancer therapy that could CERTAINTLY confound the results.”
MD Anderson presents their outcomes at ASTRO25.
“The thoracic surgery, medical, and radiation oncology team at MD Anderson presents their outcomes at ASTRO25 for the 21% of pts with LA-NSCLC started on a neoadjuvant chemoICI approach who ended up getting radiation therapy instead of surgery.”
The emerging challenges of RCTs for patients with limited oligometastatic disease.
“Dr. Houda Bahig is scheduled to present a report at ASTRO25 demonstrating the emerging challenges of RCTs for patients with limited oligometastatic disease. A new frontier for Difficult Randomized Clinical Trials.”
Single-institutional experience at ASTRO25.
“The thoracic surgery, medical, and radiation oncology team at the University of Pennsylvania presents their single-institutional experience at ASTRO25 for patients with LA-NSCLC treated with neoadjuvant chemo-ICI, of whom 42% didn’t proceed to surgery.”
10-year experience with single-fraction lung SBRT.
“A group of investigators from Valencia presents their 10-year experience with single-fraction lung SBRT at ASTRO25. Their data reports 99% in-field local control with a median f/u time of 5 years.”
SBRT for staple-line recurrences.
“SBRT for staple-line recurrences after lung resection appears safe and effective, as reported at ASTRO25.”
The best way to learn at ASTRO25.
“The best way to learn at ASTRO25 just might be to take the punches in stride.”
More posts featuring Drew Moghanaki.